Literature DB >> 31277833

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.

.   

Abstract

Entities:  

Year:  2019        PMID： 31277833     DOI： 10.1016/j.jval.2019.05.002

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  1 in total

1.  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Authors:  Larissa A Korde; Mark R Somerfield; Lisa A Carey; Jennie R Crews; Neelima Denduluri; E Shelley Hwang; Seema A Khan; Sibylle Loibl; Elizabeth A Morris; Alejandra Perez; Meredith M Regan; Patricia A Spears; Preeti K Sudheendra; W Fraser Symmans; Rachel L Yung; Brittany E Harvey; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 44.544
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.